+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of HBS-301 in adults aged 18 years and older who have idiopathic hypersomnia IH, a condition characterized by excessive daytime sleepiness EDS. This Phase 3 clinical trial is randomized, double-blind, and placebo-controlled, aiming to better understand how HBS-301 affects the severity of sleepiness and other IH symptoms compared to placebo. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may choose to join an optional 1-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by 30 days of safety follow-up after treatment ends. During the trial, participants will have regular assessments including questionnaires measuring sleepiness severity using the Epworth Sleepiness Scale and other scales evaluating IH symptoms, sleep inertia, fatigue, cognition, quality of life, and work productivity. Safety monitoring includes tracking any adverse events throughout the 16 months of the study. Participants will be involved in scheduled visits for evaluations and treatment adherence, with the primary focus on changes in daytime sleepiness severity over the 8-week treatment period.

Age: 18Years +All GendersPhase 3
42 locations
P

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.

Age: 18Years +All GendersPhase 3
53 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
R

Actively Recruiting

Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
186 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of MACI compared to arthroscopic microfracture in treating young patients aged 10 to 17 years who have symptomatic cartilage or osteochondral defects in the knee. This Phase 3, multicenter, randomized clinical trial involves 45 participants who will be assigned to one of two treatment groups MACI or microfracture. The study aims to better understand which treatment provides improved pain relief and knee function in this patient population. Participants undergo a screening arthroscopy to confirm eligibility and measure cartilage lesion size before randomization. Those assigned to the microfracture group receive the procedure during this initial arthroscopy. For participants in the MACI group, a cartilage biopsy is collected and sent to a manufacturing facility to prepare the MACI implant. The MACI treatment is then implanted via arthrotomy within 12 weeks after screening. All participants follow a postoperative rehabilitation program, with adherence monitored by the study team. Participants are followed for two years after treatment to assess outcomes, including improvements in knee pain and function using the KOOS-Child questionnaire. The study collects data at various points, including baseline and 104 weeks post-treatment. Safety and effectiveness are closely monitored throughout this period to provide detailed information on each treatments impact on knee health and patient quality of life.

Age: 10Years - 17YearsAll GendersPhase 3
15 locations
E

Actively Recruiting

Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.

Age: 18Years +All GendersPhase 3
186 locations
L

Actively Recruiting

The trial investigates the long-term safety of avacopan in adults diagnosed with antineutrophil cytoplasmic antibody ANCA-associated vasculitis, a condition requiring immunosuppressive treatment. This phase 4, randomized, double-blind, placebo-controlled study aims to assess treatment-emergent adverse events and other safety markers over a period of up to 5 years. Participants include those newly diagnosed or experiencing a relapse of granulomatosis with polyangiitis or microscopic polyangiitis, with specific antibody and disease activity criteria. Participants are randomly assigned to one of three groups avacopan 30 mg twice daily for 5 years with standard immunosuppressive therapy, avacopan 30 mg twice daily for 1 year followed by placebo for 4 years with standard therapy, or placebo twice daily for 5 years with standard therapy. All participants receive background immunosuppressive care as determined by their doctors. Treatments are administered orally, and the study maintains double-blinding to compare safety and efficacy outcomes across groups. Throughout the study, participants undergo regular safety assessments including vital signs, blood tests, serum chemistry, and urine analysis to monitor any significant changes from baseline. Researchers evaluate adverse events, remission status, kidney function, health survey scores, and glucocorticoid or immunosuppressant use over the 5-year period. The study includes continuous monitoring for serious adverse events, treatment withdrawals, and deaths related to the intervention, ensuring detailed long-term safety data collection.

Age: 18Years - 100YearsAll GendersPhase 4
83 locations
S

Actively Recruiting

Researchers are evaluating the safety and symptom improvement of ALKS 7290 tablets compared with placebo in adults diagnosed with Attention Deficit Hyperactivity Disorder ADHD. This phase 2, randomized, double-blind study aims to understand how ALKS 7290 affects ADHD symptoms over a four-week period. The study involves adult participants aged 18 to 65 who meet specific diagnostic criteria and have moderate or worse symptom severity. Participants will take ALKS 7290 tablets or placebo capsules daily by mouth for 4 weeks. The trial includes multiple dose levels of ALKS 7290 alongside a placebo group, with treatment effects compared across these groups. The study is designed with a parallel group model and triple blinding to ensure unbiased assessment. Throughout the study, participants will be regularly evaluated for changes in their ADHD symptoms using the Attention Deficit Disorder Investigator Symptom Rating Scale AISRS and the Clinical Global Impression-Severity scale. Safety is monitored by tracking adverse events up to six weeks. Participant health, medication stability, and symptom severity are assessed before and during the trial to measure treatment impact and ensure well-being.

Age: 18Years - 65YearsAll GendersPhase 2
28 locations
E

Actively Recruiting

Researchers are evaluating how well intranasal esketamine works alongside standard care to quickly reduce symptoms of major depressive disorder MDD in adolescents with acute suicidal thoughts or behaviors. The study compares esketamine plus comprehensive standard care to a psychoactive placebo plus standard care to understand its effectiveness and safety in this population. Participants will be randomly assigned to one of two groups receiving treatment twice weekly for 4 weeks. One group receives intranasal esketamine starting at 84 mg, possibly reduced to 56 mg based on investigator judgment, along with oral placebo. The other group receives oral midazolam and intranasal placebo following a similar dosing schedule. The study allows dose flexibility between 56 mg and 84 mg for esketamine during treatment. During the study, participants will be monitored through various assessments including depression rating scales and measures of suicidality at baseline, 24 hours after the first dose, and throughout the 25-day treatment period. Researchers will evaluate changes in depressive symptoms, suicidality severity, and quality of life. Safety and adherence will be carefully observed, with the study continuing until primary outcome evaluation and completion by 2031.

Age: 12Years - 17YearsAll GendersPhase 3
49 locations

1-10 of 26

1